Sandoz to acquire biosimilar CIMERLI from Coherus BioSciences to expand ophthalmology portfolio
In a significant development within the pharmaceutical and healthcare industry, Sandoz, a global leader in generic and biosimilar medicines, announced its strategic acquisition of the ... Read More
FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11
Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More
Samsung Bioepis partners with C-Bridge Capital to expand biosimilar portfolio in China
Samsung Bioepis, a South Korean leader in biopharmaceuticals, has struck a deal with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in ... Read More
FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment
Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it ... Read More